Pharmacogenetic Study of Different Hormone Therapies in Recent Menopause Women

Plain-language summary

This study examined the effects of different hormone therapies (Estradiol with Progesterone, or Estradiol with Drospirenone) in relation to genetic characteristics in recently menopausal women. It enrolled women aged 42 to 58 whose last menstrual period was between 6 months and 3 years earlier. It was conducted as a trial with no assigned phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

Not Applicable

Status

Completed

Sponsor

Denusa Wiltgen

Intervention

Estradiol and Progesterone, Estradiol and Drospirenone

Start date

3/1/2007

Estimated completion

4/1/2011

Countries

Brazil

Related genes

Locations

• Porto Alegre, Brazil

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion criteria:

* last menstrual period between 6 months and 3 years before the beginning of the study plus FSH levels higher than 35 IU/L;
* age between 42 and 58 years;
* no use of any medication known to interfere with hormonal, glucose, or lipoprotein levels in the past 3 months;
* no use of steroidal or no steroidal anti-inflammatory drugs in the last 15 days.

Exclusion criteria:

* patients with diabetes,
* previous hysterectomy,
* endometrial thickness \>0.5cm,
* history of cancer,
* thromboembolism, or
* established cardiovascular disease